Evidence map›Paper›PMID 28264843›Full record

ArticleAntimicrobial agents and chemotherapy2017

A Risk Score for Fluconazole Failure among Patients with Candidemia.

Luis Ostrosky-Zeichner, Rachel Harrington, Nkechi Azie, Hongbo Yang, Nanxin Li, Jing Zhao, Valerie Koo, Eric Q Wu

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. OralCurrent medical mycology · 2022
    Article
  4. Article
  5. Overview on the Infections Related to RarePathogens (Basel, Switzerland) · 2022
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Luis Ostrosky-ZeichnerDivision of Infectious Diseases, McGovern Medical School, Houston, Texas, USA Luis.Ostrosky-Zeichner@uth.tmc.edu.
Rachel HarringtonAstellas Pharma US, Northbrook, Illinois, USA.
Nkechi AzieAstellas Pharma US, Northbrook, Illinois, USA.
Hongbo YangAnalysis Group, Inc., Boston, Massachusetts, USA.
Nanxin LiAnalysis Group, Inc., Boston, Massachusetts, USA.
Jing ZhaoAnalysis Group, Inc., Boston, Massachusetts, USA.
Valerie KooAnalysis Group, Inc., Boston, Massachusetts, USA.
Eric Q WuAnalysis Group, Inc., Boston, Massachusetts, USA.
Analysis Group (United States) · USAstellas Pharma (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to develop a prediction model to identify patients with candidemia who were at high risk of failing fluconazole treatment. Adult patients in the United States with candidemia who received fluconazole during hospitalization were selected from the Cerner Health Facts Hospital Database (04/2004 to 03/2013). Fluconazole failure was defined as switching/adding another antifungal, positive

Indexed as

Antifungal AgentsCandidaCandidemiaDrug Resistance, FungalFemaleFluconazoleHumansMaleMicrobial Sensitivity TestsMiddle AgedModels, TheoreticalRisk FactorsTreatment FailureAntifungal AgentsFluconazoleCandidacandidemiafailurefluconazoleinvasive candidiasisrisk score

Identifiers

PMID28264843
PMCPMC5404593
OpenAlexW2591764676

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.